Cartesian Therapeutics, Inc.

Stage 3 · Topping · week 6

As of Oct 22, 2026, Cartesian Therapeutics is in Stage 3, the topping phase, now in week 6 (since Sep 17, 2026). It closed at $6.41, 39.5% below its 52-week high and below its 200-day average, which is falling.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. More about the company

$6.41

-0.16% today

$194M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is RNAC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 26w

S4 20w

S4 25w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 6w → S1 1w → S4 3w → S1 3w → S4 26w → S1 6w → S2 3w → S3 1w → S4 10w → S1 8w → S2 4w → S1 1w → S4 6w → S1 2w → S4 20w → S1 9w → S4 25w → S1 2w → S4 6w → S1 2w → S4 4w → S1 2w → S2 11w → S3 5w current

Total tracked: 165 weeks across 24 stage runs.

RNAC among Biotechnology283rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…283	RNACCartesian Therapeutics, Inc.	Stage 3 · wk 6	33	−18.6%

vs 52W High

-39.5%

$5.84 lo$10.59 hi

39.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 6

1w13w26w

Week 6, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-16.6%

200 DMA: $7.69 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.66x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-18.6%

-18.7%

-8.0%

YTD

-5.2%

-30.9%

Scan Membership

Breakout Watch

Latest: 2024-12-04

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 6 · Vol 0.66x

2026-10-21S3

Wk 5 · Vol 0.72x

2026-10-20S3

Wk 5 · Vol 1.27x

2026-10-19S3

Wk 5 · Vol 1.54x

2026-10-16S3

Wk 5 · Vol 0.86x

2026-10-15S3

Wk 5 · Vol 0.66x

2026-10-14S3

Wk 4 · Vol 1.30x

2026-10-13S3

Wk 4 · Vol 1.66x

2026-10-12S3

Wk 4 · Vol 0.82x

2026-10-09S3

Wk 4 · Vol 0.87x

2026-10-08S3

Wk 4 · Vol 1.64x

2026-10-07S3

Wk 3 · Vol 0.66x

Moving averages & range

50 DMA

$8.09

200 DMA

$7.69

52W High

$10.59

52W Low

$5.84

5D Low

$6.08

Resistance levels (recent highs)

20d High

$7.41

60d High

$10.49

120d High

$10.59

250d High

$10.59

Next resistance

+15.6%

to 20d High

Earnings Growth (YoY)

-8.0%

Revenue —

Dividend Yield

0.00%

P/B -1.5

Cartesian Therapeutics: quick answers

What stage is Cartesian Therapeutics in?

As of Oct 22, 2026, Cartesian Therapeutics (RNAC) is in Stage 3, the topping phase. It entered Stage 3 on Sep 17, 2026 and is in week 6. What the four stages mean

Is Cartesian Therapeutics in an uptrend?

Its uptrend has stalled. Cartesian Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 16.6% below its 200-day average, which is falling.

How far is Cartesian Therapeutics from its 52-week high?

Cartesian Therapeutics closed at $6.41 on Oct 22, 2026, 39.5% below its 52-week high of $10.59. Its 52-week low is $5.84.

How has Cartesian Therapeutics performed over the past year?

As of Oct 22, 2026, Cartesian Therapeutics is down 30.9% over the past year and down 5.2% so far in 2026.

Which sector and industry is Cartesian Therapeutics in?

Cartesian Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.